Citation Impact
Citing Papers
Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
2001 StandoutScienceNobel
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
2001 StandoutScienceNobel
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production
2005 StandoutNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
In vitro and In vivo Models Analyzing von Hippel-Lindau Disease-Specific Mutations
2004
Hallmarks of Cancer: The Next Generation
2011 Standout
Hypoxia and intra-complex genetic suppressors rescue complex I mutants by a shared mechanism
2024 StandoutNobel
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations
2007 StandoutNobel
Comparative Sequence Analysis of the VHL Tumor Suppressor Gene
2000
Homozygous Inactivation of theNF1Gene in Bone Marrow Cells from Children with Neurofibromatosis Type 1 and Malignant Myeloid Disorders
1997
A Toll-like receptor recognizes bacterial DNA
2000 StandoutNature
An Analysis of Phenotypic Variation in the Familial Cancer Syndrome von Hippel–Lindau Disease: Evidence for Modifier Effects
1998
Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene
2002
C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation
2001 StandoutNobel
Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours
1994
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
2002 StandoutNatureNobel
Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect
1995
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Multiple Neuroendocrine Tumors of the Pancreas in von Hippel-Lindau Disease Patients
1998
Histopathology and Molecular Genetics of Multiple Cysts and Microcystic (Serous) Adenomas of the Pancreas in von Hippel-Lindau Patients
2000
Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues
1997 StandoutNobel
The pressure rises: update on the genetics of phaeochromocytoma
2002
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
von Hippel-Lindau disease: Clinical and molecular perspectives
2001
Familial Hemiplegic Migraine and Episodic Ataxia Type-2 Are Caused by Mutations in the Ca2+ Channel Gene CACNL1A4
1996 Standout
Renal-Cell Carcinoma
1996 Standout
A genetic model for colorectal tumorigenesis
1990 Standout
Clinical Characteristics of Ocular Angiomatosis in von Hippel-Lindau Disease and Correlation With Germline Mutation
1999
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
1999 StandoutNatureNobel
Yeast RNA Polymerase II at 5 Å Resolution
1999 StandoutNobel
Molecular Genetic Analysis of the von Hippel-Lindau Disease Tumor Suppressor Gene in Familial and Sporadic Cerebellar Hemangioblastomas
1997
Retinal angiomatosis and von Hippel-Lindau disease
2000
von Hippel-Lindau Disease
1997 StandoutNobel
The discovery of immunostimulatory DNA sequence
2001
Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC
1999
Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein
1995 Science
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease
2001
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein
1999 StandoutNobel
Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and 22
1994
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF
2001
The pVHL-associated SCF ubiquitin ligase complex: Molecular genetic analysis of elongin B and C, Rbx1 and HIF-1α in renal cell carcinoma
2001 StandoutNobel
von Hippel-Lindau disease
2003 Standout
Mutations in the p53 gene occur in diverse human tumour types
1989 StandoutNature
Renal-Cell Carcinoma
2005
Cytogenetic analysis of epithelial renal‐cell tumors: Relationship with a new histopathological classification
1993
The von Hippel-Lindau Gene Product Inhibits Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Renal Cell Carcinoma by Blocking Protein Kinase C Pathways
1997
Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL
2002
Genetic alterations in sporadic renal-cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p
1994
The natural history of hemangioblastomas of the central nervous system in patients with von Hippel—Lindau disease
2003
Mechanisms of angiogenesis
1997 StandoutNature
von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease
1997
Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL
1997
Pheochromocytoma: The Expanding Genetic Differential Diagnosis
2003
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene
1998
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
2005 StandoutNobel
VHL-gene Deletion in Single Renal Tubular Epithelial Cells and Renal Tubular Cysts: Further Evidence for a Cyst-dependent Progression Pathway of Clear Cell Renal Carcinoma in von Hippel-Lindau Disease
2010
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
2002 StandoutNobel
The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase
2007 StandoutNobel
Sporadic Pheochromocytomas Are Rarely Associated with Germline Mutations in thevhlTumor Suppressor Gene or theretProtooncogene1
1997
Differences in Allelic Distribution of Two Polymorphisms in the VHL-Associated GeneCUL2in Pheochromocytoma Patients without SomaticCUL2Mutations1
1999
Differential Genetic Alterations in von Hippel-Lindau Syndrome-Associated and Sporadic Pheochromocytomas1
2000
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma
1996
Clinical and Genetic Aspects of Phaeochromocytoma
2003
An Important von Hippel-Lindau Tumor Suppressor Domain Mediates Sp1-Binding and Self-Association
1999
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
2000 StandoutNobel
The VHL tumour-suppressor gene paradigm
1998 StandoutNobel
Activation of Sp1-mediated Vascular Permeability Factor/Vascular Endothelial Growth Factor Transcription Requires Specific Interaction with Protein Kinase C ζ
1998
Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease
2000
Software and database for the analysis of mutations in the VHL gene
1998
Hereditary Papillary Renal Cell Carcinoma
1994
VHL Gene Deletion and Enhanced VEGF Gene Expression Detected in the Stromal Cells of Retinal Angioma
1999
PERCUTANEOUS RADIO FREQUENCY ABLATION OF SMALL RENAL TUMORS: INITIAL RESULTS
2002
A genetic register for von Hippel-Lindau disease.
1996
Inactivation of the von Hippel–Lindau ( VHL ) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL ‐independent pathway in clear cell renal tumourigenesis
1998
p53 Mutations in Human Cancers
1991 StandoutScience
Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations.
1996
Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors.
1997
Transcription-Dependent Nuclear-Cytoplasmic Trafficking Is Required for the Function of the von Hippel-Lindau Tumor Suppressor Protein
1999
Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.
1992 StandoutNobel
Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer.
1995
THE RELATIONSHIP BETWEEN RENAL TUMOR SIZE AND METASTASES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE
2004
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.
1996
Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
1995 StandoutScienceNobel
Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase
1999 StandoutScienceNobel
Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL −/− clear cell renal carcinoma
2017 StandoutNobel
von Hippel-Lindau Disease
2006 StandoutNobel
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
2002 StandoutNobel
Cancer Cell Cycles
1996 StandoutScience
Frequency and structure of p53 rearrangements in human osteosarcoma.
1990
Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations.
1995
Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
1996
Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products
2000
RENAL CANCER IN FAMILIES WITH HEREDITARY RENAL CANCER: PROSPECTIVE ANALYSIS OF A TUMOR SIZE THRESHOLD FOR RENAL PARENCHYMAL SPARING SURGERY
1999
Papillary renal cell carcinoma.A clinical, radiologic, and pathologic study of 34 cases
1976
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
2019 StandoutNobel
Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations.
1995
MUTATION OF THE VON HIPPEL-LINDAU TUMOUR SUPPRESSOR GENE IN CAPILLARY HAEMANGIOBLASTOMAS OF THE CENTRAL NERVOUS SYSTEM
1996
The discovery of immunostimulatory DNA sequence
2000
Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.
1994
Tumor Suppressor Gene Allelic Loss in Human Renal Cancers
1993
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Gene
2020
pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation
1998 StandoutNobel
Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease.
1996
Reactivation of Hepatic EPO Synthesis in Mice After PHD Loss
2010 StandoutScienceNobel
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
1999 StandoutScienceNobel
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
1996 StandoutNobel
Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma.
1995
Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.
1996
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
2002 StandoutScienceNobel
AACR Centennial Series: The Biology of Cancer Metastasis: Historical Perspective
2010
Vascular tumors in livers with targeted inactivation of the von Hippel–Lindau tumor suppressor
2001
Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study.
2002
Genomic organization and chromosomal localization of the humanCUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development
1999
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
PREVALENCE, MORPHOLOGY AND BIOLOGY OF RENAL CELL CARCINOMA IN VON HIPPEL-LINDAU DISEASE COMPARED TO SPORADIC RENAL CELL CARCINOMA
1998
Prevalence of Microscopic lesions in Grossly Normal Renal Parenchyma from Patients with von Hippel-Lindau Disease, Sporadic Renal Cell Carcinoma and No Renal Disease: Clinical Implications
1995
The von Hippel-Lindau Tumor Suppressor Gene Product Interacts with Sp1 To Repress Vascular Endothelial Growth Factor Promoter Activity
1997
The Biology of Cancer Invasion and Metastasis
1978
Von Hippel-Lindau Syndrome
1999
Factors regulating the transcriptional elongation activity of RNA polymerase II
1998
Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas.
1995
Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.
1994
Consequences of Direct Genetic Testing for Germline Mutations in the Clinical Management of Families With Multiple Endocrine Neoplasia, Type II
1995
Structural Basis of Transcription: RNA Polymerase II at 2.8 Ångstrom Resolution
2001 StandoutScienceNobel
Inhibition of the oxygen sensor PHD2 in the liver improves survival in lactic acidosis by activating the Cori cycle
2015 StandoutNobel
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size.
1995
CLINICAL AND GENETIC CHARACTERIZATION OF PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU FAMILIES: COMPARISON WITH SPORADIC PHEOCHROMOCYTOMA GIVES INSIGHT INTO NATURAL HISTORY OF PHEOCHROMOCYTOMA
1999
The Molecular Basis of Von Hippel-Lindau Disease
1997 StandoutNobel
Works of B. Zbar being referenced
Birt-Hogg-Dubé Syndrome
1999
Genetic Changes in Human Adrenocortical Carcinomas
1989
Genetic linkage between Von Hippel—Lindau disease and three microsatellite polymorphisms refines the localisation of the VHL locus
1993
The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients.
1992
Molecular mapping of deletion sites in the short arm of chromosome 3 in human lung cancer
1990
Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von hippel‐lindau disease‐associated, and familial pheochromocytoma
1995
Taql and Pstl RFLPs in the von Hippel–Lindau disease gene (VHL)
1993
Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene
1995
Detailed mapping of germline deletions of the von Hippel—Lindau disease tumour suppressor gene
1994
Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. I. Tumor growth and metastasis.
1972
Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens.
1996
Identification of intragenic mutations in the Von Hippel — Lindau disease tumour suppressor gene andcorrelation with disease phenotype
1994
Tumor cells transfected with the neomycin resistance gene (neo) contain unique genetic markers useful for identification of tumor recurrence and metastasis.
1987
Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines.
1994
Immunologic approaches to the treatment of human cancer based on a guinea pig model
1976
Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis.
1995
Molecular analysis of genetic changes in the origin and development of renal cell carcinoma.
1991